Prevenar 13 Drug Interactions

Different injectable vaccines should always be given at different vaccination sites.
Infants and children aged 6 weeks to 5 years: Prevenar 13 can be given with any of the following vaccine antigens, either as monovalent or combination vaccines: diphtheria, tetanus, acellular or whole-cell pertussis, Haemophilus influenzae type b, inactivated poliomyelitis, hepatitis A, hepatitis B, meningococcal serogroup C, measles, mumps, rubella, varicella, and rotavirus.
Prevenar 13 can also be given concomitantly between 12-23 months of age with the tetanus toxoid conjugated meningococcal polysaccharide serogroups A, C, W and Y vaccine.
Data from a post-marketing clinical study evaluating the impact of prophylactic use of antipyretics on the immune response to Prevenar 13 suggest that concomitant administration of paracetamol may reduce the immune response to Prevenar 13 after the infant series. Responses to the booster dose administered at 12 months were unaffected. The clinical significance of this observation is unknown.
Children and adolescents 6 to 17 years of age: In children and adolescents, there are no data on the concomitant administration of Prevenar 13 with human papillomavirus vaccine (HPV), meningococcal protein conjugate vaccine (MCV4), or tetanus, diphtheria and acellular pertussis vaccine (Tdap).
Adults 18 to 49 years of age: No data are available regarding concomitant use with other vaccines.
Adults 50 years and older: Prevenar 13 can be administered concomitantly with trivalent or quadrivalent inactivated influenza vaccine (TIV or QIV) (see Pharmacology: Pharmacodynamics under Actions).
In two studies conducted in adults aged 50-59 and 65 years and older, it was demonstrated that Prevenar 13 may be given concomitantly with TIV. The responses to all three TIV antigens were comparable when TIV was given alone or concomitantly with Prevenar 13.
When Prevenar 13 was given concomitantly with TIV, the immune responses to Prevenar 13 were lower compared to when Prevenar 13 was given alone. The clinical significance of this is unknown.
Concomitant use with other vaccines has not been investigated.
Different injectable vaccines should always be given at different vaccination sites.
Concomitant administration of Prevenar 13 and PPSV23 has not been studied. In clinical studies when Prevenar 13 was given 1 year after PPSV23, the immune responses were lower for all serotypes compared to when Prevenar 13 was given to subjects not previously immunised with PPSV23. The clinical significance of this is unknown.